Ernexa TherapeuticsERNA +3.68%30 Buyback Yield % is -226.04 as of Jul. 10, 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 742 Biotechnology companies, Ernexa Therapeutics ranks worse than 95.42% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Ernexa Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Ernexa Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERNA vs PMCB, SYBX, ASBP: Buyback Yield % Comparison
For the Biotechnology subindustry, Ernexa Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ernexa Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ernexa Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Ernexa Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ernexa Therapeutics (ERNA) has a Buyback Yield % of -226.04 as of Jul. 10, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ernexa Therapeutics and its competitors. According to the industry distribution chart, Ernexa Therapeutics ranks #708 out of 742 companies in the Biotechnology industry, placing it in the top 95.4%.
Is Ernexa Therapeutics' Buyback Yield % too high?
Ernexa Therapeutics' current Buyback Yield % is -226.04. Based on the distribution chart, Ernexa Therapeutics ranks #708 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Buyback Yield % compare to PMCB and SYBX?
According to the Biotechnology industry distribution chart, Ernexa Therapeutics ranks #708 out of 742 companies for Buyback Yield %. This places Ernexa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current Buyback Yield % is -226.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Buyback Yield % of -226.04. The current Buyback Yield % is -226.04. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Buyback Yield % is -226.04 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score
Get the complete analysis for ERNA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERNA has been successfully added to your 
